PD-L1 is also expressed on dendritic cells and myeloid-derived suppressor cells in MM patients (14–16); therefore, the anti-PD-L1 monoclonal antibody atezolizumab (Atezo) may have therapeutic application in MM (17). The gene discussed is CD274; the disease is Miyoshi myopathy.